FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2898064986> ?p ?o ?g. }

• W2898064986 endingPage "89" @default.
• W2898064986 startingPage "75" @default.
• W2898064986 abstract "Recent studies point to the evolution of drug resistance in lung cancer as being centered, at least in part, on the upregulation of various genes involved in controlling efflux or drug inactivation. Among the most important of these genes is Nuclear Factor Erythroid 2-Related Factor (NRF2), considered the master regulator of 100–200 target genes involved in cellular responses to oxidative and/or electrophilic stress. With increased focus on the development of combinatorial approaches for cancer treatment, we utilized CRISPR/Cas9 to disable the NRF2 gene in lung cancer cells by disrupting the NRF2 nuclear export signal (NES) domain; phenotypically, the protein is largely blocked from transiting into the nucleus after translation. In tissue culture, cells with this gene knockout were found to have a reduced proliferation phenotype and are more sensitive to chemotherapeutic agents, such as cisplatin and carboplatin. These observations were confirmed in xenograft mouse models wherein the homozygous knockout cells proliferate at a slower rate than the wild-type cells, even in the absence of drug treatment. Tumor growth was arrested for a period of 16 days, with a dramatic decrease in tumor volume being observed in samples receiving the combined action of CRISPR-directed gene editing and chemotherapy. Recent studies point to the evolution of drug resistance in lung cancer as being centered, at least in part, on the upregulation of various genes involved in controlling efflux or drug inactivation. Among the most important of these genes is Nuclear Factor Erythroid 2-Related Factor (NRF2), considered the master regulator of 100–200 target genes involved in cellular responses to oxidative and/or electrophilic stress. With increased focus on the development of combinatorial approaches for cancer treatment, we utilized CRISPR/Cas9 to disable the NRF2 gene in lung cancer cells by disrupting the NRF2 nuclear export signal (NES) domain; phenotypically, the protein is largely blocked from transiting into the nucleus after translation. In tissue culture, cells with this gene knockout were found to have a reduced proliferation phenotype and are more sensitive to chemotherapeutic agents, such as cisplatin and carboplatin. These observations were confirmed in xenograft mouse models wherein the homozygous knockout cells proliferate at a slower rate than the wild-type cells, even in the absence of drug treatment. Tumor growth was arrested for a period of 16 days, with a dramatic decrease in tumor volume being observed in samples receiving the combined action of CRISPR-directed gene editing and chemotherapy." @default.
• W2898064986 created "2018-10-26" @default.
• W2898064986 creator A5034242696 @default.
• W2898064986 creator A5077581350 @default.
• W2898064986 creator A5081138565 @default.
• W2898064986 creator A5088719507 @default.
• W2898064986 date "2018-12-01" @default.
• W2898064986 modified "2023-10-05" @default.
• W2898064986 title "Functional Gene Knockout of NRF2 Increases Chemosensitivity of Human Lung Cancer A549 Cells In Vitro and in a Xenograft Mouse Model" @default.
• W2898064986 cites W1538676860 @default.
• W2898064986 cites W1974208182 @default.
• W2898064986 cites W1988227670 @default.
• W2898064986 cites W1990598806 @default.
• W2898064986 cites W2013654121 @default.
• W2898064986 cites W2031211461 @default.
• W2898064986 cites W2045435533 @default.
• W2898064986 cites W2050480410 @default.
• W2898064986 cites W2053047691 @default.
• W2898064986 cites W2068878269 @default.
• W2898064986 cites W2077296816 @default.
• W2898064986 cites W2077950988 @default.
• W2898064986 cites W2081634649 @default.
• W2898064986 cites W2091070104 @default.
• W2898064986 cites W2095908065 @default.
• W2898064986 cites W2096261947 @default.
• W2898064986 cites W2101825558 @default.
• W2898064986 cites W2104718696 @default.
• W2898064986 cites W2106070783 @default.
• W2898064986 cites W2129360604 @default.
• W2898064986 cites W2132157071 @default.
• W2898064986 cites W2135144012 @default.
• W2898064986 cites W2144660856 @default.
• W2898064986 cites W2145835533 @default.
• W2898064986 cites W2160982674 @default.
• W2898064986 cites W2168340462 @default.
• W2898064986 cites W2168973737 @default.
• W2898064986 cites W2171499496 @default.
• W2898064986 cites W2199695484 @default.
• W2898064986 cites W2227073990 @default.
• W2898064986 cites W2302348986 @default.
• W2898064986 cites W2338576144 @default.
• W2898064986 cites W2502310207 @default.
• W2898064986 cites W2507289596 @default.
• W2898064986 cites W2507654187 @default.
• W2898064986 cites W2511861812 @default.
• W2898064986 cites W2571296550 @default.
• W2898064986 cites W2581964534 @default.
• W2898064986 cites W2587567491 @default.
• W2898064986 cites W2588556918 @default.
• W2898064986 cites W2735952693 @default.
• W2898064986 cites W2739183735 @default.
• W2898064986 cites W2744161470 @default.
• W2898064986 cites W2774073810 @default.
• W2898064986 cites W2781525129 @default.
• W2898064986 cites W2789250554 @default.
• W2898064986 cites W2789550512 @default.
• W2898064986 cites W811643587 @default.
• W2898064986 doi "https://doi.org/10.1016/j.omto.2018.10.002" @default.
• W2898064986 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6251792" @default.
• W2898064986 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30505938" @default.
• W2898064986 hasPublicationYear "2018" @default.
• W2898064986 type Work @default.
• W2898064986 sameAs 2898064986 @default.
• W2898064986 citedByCount "48" @default.
• W2898064986 countsByYear W28980649862019 @default.
• W2898064986 countsByYear W28980649862020 @default.
• W2898064986 countsByYear W28980649862021 @default.
• W2898064986 countsByYear W28980649862022 @default.
• W2898064986 countsByYear W28980649862023 @default.
• W2898064986 crossrefType "journal-article" @default.
• W2898064986 hasAuthorship W2898064986A5034242696 @default.
• W2898064986 hasAuthorship W2898064986A5077581350 @default.
• W2898064986 hasAuthorship W2898064986A5081138565 @default.
• W2898064986 hasAuthorship W2898064986A5088719507 @default.
• W2898064986 hasBestOaLocation W28980649861 @default.
• W2898064986 hasConcept C104317684 @default.
• W2898064986 hasConcept C121608353 @default.
• W2898064986 hasConcept C127561419 @default.
• W2898064986 hasConcept C142724271 @default.
• W2898064986 hasConcept C182704531 @default.
• W2898064986 hasConcept C2776256026 @default.
• W2898064986 hasConcept C2776694085 @default.
• W2898064986 hasConcept C2778239845 @default.
• W2898064986 hasConcept C2781451048 @default.
• W2898064986 hasConcept C502942594 @default.
• W2898064986 hasConcept C54355233 @default.
• W2898064986 hasConcept C71924100 @default.
• W2898064986 hasConcept C77957584 @default.
• W2898064986 hasConcept C86803240 @default.
• W2898064986 hasConcept C96232424 @default.
• W2898064986 hasConcept C98108389 @default.
• W2898064986 hasConceptScore W2898064986C104317684 @default.
• W2898064986 hasConceptScore W2898064986C121608353 @default.
• W2898064986 hasConceptScore W2898064986C127561419 @default.
• W2898064986 hasConceptScore W2898064986C142724271 @default.
• W2898064986 hasConceptScore W2898064986C182704531 @default.
• W2898064986 hasConceptScore W2898064986C2776256026 @default.
• W2898064986 hasConceptScore W2898064986C2776694085 @default.

• next